S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 63,951.34 +0.08%
Next Bullish Trade
Sign in
BAYRY

Bayer Aktiengesellschaft OQX · BAYRY

$13.80 +0.20 (+1.47%)
Extended · +1.34σ

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · BAYRY

Momentum reads · latest daily bar
Last
$13.80
+0.20 (+1.47%)
Mkt cap
$54.2B
Healthcare
RSI(14)
61.7
neutral
Stochastic %K
41.6
neutral
MFI(14)
40.1
neutral
ADX(14)
31.5
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $13.4B $2.8B $3.5B $-2.2B 20.6% 26.3%
2025-12-31 $11.4B $-3.8B $4.3B $3.4B -32.8% 38.0%
2025-09-30 $9.7B $-1.0B $-0.5B $0.8B -10.0% -5.6%
2025-06-30 $10.7B $-0.2B $0.0B $0.6B -1.9% 0.1%
2025-03-31 $13.7B $1.3B $2.3B $-1.4B 9.5% 16.9%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare BAYRY vs peers

Line BAYRY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing BAYRY AAPL× JNJ× NVDA× LLY×
Sector peers + UNH + MRK + ABBV + PFE + TMO
Popular + MSFT + AMZN + GOOG + META + TSLA + AVGO
Verdict
Weighted score 0-100 across 5 tickers · best in green
#3
BAYRY
score 50.6
5/5 inputs
Ranks third despite strong momentum of 72 due to catastrophic quality score of 7 from negative margins.
value 80growth 31quality 7momentum 72sentiment 50
#4
AAPL
score 39.8
5/5 inputs
Premium valuation with forward PE of 34.6 creates weak value score of 34, dragging overall rank to fourth.
value 34growth 16quality 61momentum 80sentiment 14
#2
JNJ
score 51.2
3/5 inputs
Maximal sentiment score of 100 driven by 13% insider buying propels second-place finish despite missing fundamental data.
quality 6momentum 48sentiment 100
#5
NVDA
score 30.0
3/5 inputs
Dead-last momentum score of 0 with 20% weight crushes rank despite perfect quality score of 100.
quality 100momentum 0sentiment 0
#1
LLY
score 64.8
5/5 inputs
Dominates first place with perfect growth score of 100 from exceptional 169.9% EPS growth and 55.5% revenue expansion.
value 23growth 100quality 75momentum 48sentiment 87
BAYRY
Bayer Aktiengesellschaft
$13.80
+1.47%
Snapshot
Price 13.8
Day % 1.47
1M % 32.95
3M % 16.95
YTD % 24.44
Market cap 54229807104.0
ADV ($) 19244983.465991974
Beta 0.83
OdysseyHQ zone
Current zone Extended
Dist 21-EMA % 4.01
Dist ATR (σ) 1.34
OdysseyHQ grade
Confluence 1
Valuation
P/E (ttm)
P/E (fwd) 11.139633
P/S 1.1986607
EV/EBITDA 8.523
P/B 1.6485983
FCF yield 0.1349
PEG 4.61
Growth
Revenue yoy -0.024
EPS yoy 1.129
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.59918
Operating margin 0.26319
Net margin -0.04765
ROE -0.06928
ROA 0.03637
Debt / Equity 1.34
Interest cov. -0.38
Technicals
RSI(14) 61.7
MACD signal neutral
vs 50-DMA 17.38
vs 200-DMA 26.78
vs 52w high -9.39
HV-30 59.0
Sentiment
Analyst rec 2.25
Target upside 10.33
Insider buy-sell 90d
Risk
Short interest
Days to cover 0.0
Next earnings 2026-08-04
Full BAYRY dashboard →
AAPL
Apple Inc.
$333.74
+0.14%
Snapshot
Price 333.74
Day % 0.14
1M % 11.53
3M % 26.7
YTD % 23.15
Market cap 4901757779968.0
ADV ($) 18299230656.54297
Beta 1.097
OdysseyHQ zone
Current zone Blow-off
Dist 21-EMA % 7.28
Dist ATR (σ) 2.78
OdysseyHQ grade
Confluence 1
Valuation
P/E (ttm) 40.306763
P/E (fwd) 34.625034
P/S 10.858001
EV/EBITDA 30.742
P/B 45.969696
FCF yield 0.0206
PEG 2.54
Growth
Revenue yoy 0.166
EPS yoy 0.218
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.47862
Operating margin 0.32275
Net margin 0.27152002
ROE 1.4147099
ROA 0.26229
Debt / Equity 0.8
Interest cov.
Technicals
RSI(14) 71.6
MACD signal bull
vs 50-DMA 10.27
vs 200-DMA 21.71
vs 52w high -0.37
HV-30 34.2
Sentiment
Analyst rec 2.04255
Target upside -5.38
Insider buy-sell 90d -5
Risk
Short interest 0.9599999499999999
Days to cover 2.11
Next earnings 2026-07-30
Full AAPL dashboard →
JNJ
JNJ
$253.04
+1.23%
Snapshot
Price 253.04
Day % 1.23
1M % 7.59
3M % 7.89
YTD % 22.04
Market cap
ADV ($)
Beta
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 0.93
Dist ATR (σ) 0.38
OdysseyHQ grade
Confluence 1
Valuation
P/E (ttm)
P/E (fwd)
P/S
EV/EBITDA
P/B
FCF yield
PEG
Growth
Revenue yoy
EPS yoy
FCF yoy
Revenue trend 8Q
Quality
Gross margin
Operating margin
Net margin
ROE
ROA
Debt / Equity
Interest cov. 34.55
Technicals
RSI(14) 54.4
MACD signal neutral
vs 50-DMA 6.03
vs 200-DMA 13.51
vs 52w high -6.08
HV-30 29.3
Sentiment
Analyst rec
Target upside
Insider buy-sell 90d 13
Risk
Short interest
Days to cover
Next earnings
Full JNJ dashboard →
NVDA
NVDA
$202.81
-2.21%
Snapshot
Price 202.81
Day % -2.21
1M % -2.22
3M % 2.25
YTD % 7.39
Market cap
ADV ($)
Beta
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % -0.9
Dist ATR (σ) -0.25
OdysseyHQ grade
Confluence 2
Valuation
P/E (ttm)
P/E (fwd)
P/S
EV/EBITDA
P/B
FCF yield
PEG
Growth
Revenue yoy
EPS yoy
FCF yoy
Revenue trend 8Q
Quality
Gross margin
Operating margin
Net margin
ROE
ROA
Debt / Equity
Interest cov. 547.14
Technicals
RSI(14) 48.2
MACD signal bull
vs 50-DMA -3.38
vs 200-DMA 5.41
vs 52w high -14.26
HV-30 41.6
Sentiment
Analyst rec
Target upside
Insider buy-sell 90d -5
Risk
Short interest
Days to cover
Next earnings
Full NVDA dashboard →
LLY
LLY
$1179.11
+0.85%
Snapshot
Price 1179.11
Day % 0.85
1M % 5.04
3M % 30.43
YTD % 9.14
Market cap 1051461156864.0
ADV ($) 3829619530.3234863
Beta 0.506
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 0.95
Dist ATR (σ) 0.29
OdysseyHQ grade
Confluence 1
Valuation
P/E (ttm) 41.48874
P/E (fwd) 26.255041
P/S 14.553297
EV/EBITDA 30.086
P/B 33.768936
FCF yield 0.0087
PEG 1.55
Growth
Revenue yoy 0.555
EPS yoy 1.699
FCF yoy
Revenue trend 8Q
Quality
Gross margin 0.82832
Operating margin 0.49386
Net margin 0.34986
ROE 1.07459
ROA 0.20739001
Debt / Equity 1.39
Interest cov.
Technicals
RSI(14) 54.8
MACD signal neutral
vs 50-DMA 6.28
vs 200-DMA 17.06
vs 52w high -5.63
HV-30 32.5
Sentiment
Analyst rec 1.75862
Target upside 7.74
Insider buy-sell 90d 9
Risk
Short interest 1.05
Days to cover 2.74
Next earnings 2026-08-05
Full LLY dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-11 0.79 0.62 +29.1% +3.0%
2026-03-03 0.18 0.16 +13.5% +0.4%
2025-11-11 0.17 0.13 +30.9% +5.7%
2025-08-06 0.36 0.25 +43.4% +2.1%
2025-05-13 0.70 0.69 +0.4% -10.0%
2025-03-04 0.28 0.26 +4.8% +6.5%
2024-11-12 0.06 0.17 -62.1% -3.9%
2024-08-06 0.26 0.25 +1.2% +1.0%
2024-05-12 0.76 0.42 +80.1% +1.3%
2024-03-04 0.50 0.45 +10.6% -7.7%
2023-11-08 0.10 0.27 -62.7% +0.2%
2023-08-08 0.34 0.31 +6.6% -0.3%
2023-05-11 0.81 0.54 +48.7% +0.0%
2023-02-28 0.36 0.33 +8.6% +1.1%
2022-11-08 0.28 0.22 +29.5% -3.8%
2022-08-04 0.49 0.50 -1.9% -7.1%
2022-05-10 0.93 0.77 +21.0% -8.0%
2022-03-01 0.35 0.27 +32.8% +3.9%
2021-11-09 0.30 0.30 +0.6% +0.1%
2021-08-05 0.48 0.47 +2.2% +0.2%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
BAYRY $54B 11.1 1.2 8.5 1.6 59.9% -2.4% 112.9% 13.49%
LLY $1,051B 41.5 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 31.8 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.0 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE 18.4 5.4% 9.03%
TMO $198B 29.8 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 0.17%

HolderShares% out
Kahn Brothers Group Inc. 6,513,893 0.17%
Westside Investment Management, Inc. 2,878
PNC Financial Services Group, Inc. 3,030
Atlas Capital Advisors Inc 35,510
Great Lakes Advisors LLC 119,517
Rhumbline Advisers 68,123
Salomon & Ludwin, LLC 2,141
Gamma Investing LLC 41,204
Chicago Trust Co Na 20,097
Sterling Capital Management, LLC 846

Insider activity · 90d

No insider trades for BAYRY in last 90d.

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$14.5
Mean
$15.225
High
$15.8
Analysts
4
Recommendation distribution · period 2026-07-01
6
15
7
Revision trend (2026-04-01 → 2026-07-01): net 19 → 21 +2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

No CIK found for BAYRY.

About BAYRY

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmaci…

Options picks · BAYRY

ITM + OTM ideas from the latest scan

Loading…

Congress trades · BAYRY

STOCK Act disclosures

Loading…

SEC filings & insiders · BAYRY

EDGAR · live

Loading…

Holders · BAYRY

Institutions & insider activity

Loading…